Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:EKSO

Ekso Bionics - EKSO Stock Forecast, Price & News

$1.16
-0.02 (-1.69%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$1.14
$1.25
50-Day Range
$1.16
$2.06
52-Week Range
$1.14
$3.51
Volume
41,500 shs
Average Volume
194,452 shs
Market Capitalization
$15.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Ekso Bionics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
675.9% Upside
$9.00 Price Target
Short Interest
Healthy
0.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Ekso Bionics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$20,140 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.04) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

182nd out of 1,044 stocks

General Industrial Machinery, Industry

1st out of 12 stocks

EKSO stock logo

About Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Stock News Headlines

Ekso Bionics Reports Third Quarter 2022 Results
Preview: Ekso Bionics Holdings's Earnings
Ekso Bionics Holdings, Inc. (EKSO)
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Company Calendar

Last Earnings
11/01/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
General industrial machinery,
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+675.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,760,000.00
Net Margins
-109.88%
Pretax Margin
-109.88%

Debt

Sales & Book Value

Annual Sales
$11.25 million
Book Value
$2.18 per share

Miscellaneous

Free Float
12,741,000
Market Cap
$15.24 million
Optionable
Not Optionable
Beta
1.85

Key Executives

  • Mr. Steven A. Sherman (Age 76)
    Chairman & CEO
    Comp: $100k
  • Mr. Scott W. Davis (Age 52)
    Pres & COO
  • Mr. Jerome Wong (Age 48)
    Corp. Controller, Corp. Sec. & CFO
  • Ms. Rachael Anderson
    Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt
    VP of Sales
  • Ms. Ann Cookson
    HR Director
  • Ms. Foon Lim Chwee
    Pres of APAC
  • Mr. Jason C. Jones
    Sr. VP of Product Devel.
  • Mr. Stephan Aderhold
    Sr. VP & GM of EMEA













EKSO Stock - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month target prices for Ekso Bionics' stock. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 675.9% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2022?

Ekso Bionics' stock was trading at $2.65 on January 1st, 2022. Since then, EKSO shares have decreased by 56.2% and is now trading at $1.16.
View the best growth stocks for 2022 here
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EKSO earnings forecast
.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its earnings results on Monday, November, 1st. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.58 million. Ekso Bionics had a negative trailing twelve-month return on equity of 45.07% and a negative net margin of 109.88%. During the same quarter in the previous year, the firm earned ($0.52) earnings per share.

When did Ekso Bionics' stock split?

Ekso Bionics's stock reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?
What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a number of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (2.43%), Citadel Advisors LLC (0.00%), Strategic Wealth Investment Group LLC (0.17%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $1.16.

How much money does Ekso Bionics make?

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $15.24 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.

This page (NASDAQ:EKSO) was last updated on 11/28/2022 by MarketBeat.com Staff